Debbie Rigby takes a look at the latest in research news
A 24-week randomised controlled, comparative effectiveness trial comparing extended-release naltrexone, an opioid antagonist, and sublingual buprenorphine-naloxone, a partial opioid agonist has concluded these medicines indicated for opioid dependence are equally safe and effective. In this population it is more difficult to initiate patients to extended-release naltrexone than buprenorphine-naloxone, and this negatively affected overall relapse.
Oral antihistamines are used in the management of allergic conditions. Sedating antihistamines have little role in therapeutics due to their sedative properties and interference with rapid eye movement sleep. Less sedating antihistamines are preferable and equally efficacious for allergic rhinitis, allergic conjunctivitis, acute allergic reactions and urticaria.
Aust Prescr 2018;41:42-5.
Current cumulative clinical trials data do not support efficacy of CoQ10 for treating statin-associated muscle symptoms (SAMS). This is the conclusion of a critical evaluation of published data on the efficacy of CoQ10 supplements in the prevention and treatment of SAMS. These findings may be attributable in part to methodological and pharmacological considerations.
Am J Cardiovasc Drugs. 2018;18(2):75-82.
In this cohort study of 792 130 children, the hazard of developing an allergic disease was significantly increased in those who had received acid-suppressive medications or antibiotics during the first 6 months of life. Use of these medications, which can directly cause intestinal dysbiosis, is of concern in light of increasing evidence that alterations in the human microbiome can increase the risk for allergy development.
JAMA Pediatr. Published online April 2, 2018.